StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

Equities researchers at StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report released on Thursday. The firm set a “hold” rating on the stock.

Oncternal Therapeutics Price Performance

Shares of NASDAQ ONCT opened at $0.53 on Thursday. Oncternal Therapeutics has a 52-week low of $0.53 and a 52-week high of $13.14. The company’s 50-day simple moving average is $0.56 and its 200-day simple moving average is $2.27. The firm has a market cap of $1.56 million, a price-to-earnings ratio of -0.05 and a beta of 1.18.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.